PMID- 20182533
OWN - NLM
STAT- MEDLINE
DCOM- 20100614
LR  - 20211020
IS  - 1740-2530 (Electronic)
IS  - 1740-2522 (Print)
IS  - 1740-2522 (Linking)
VI  - 2009
DP  - 2009
TI  - Cancer vaccine by fusions of dendritic and cancer cells.
PG  - 657369
LID - 10.1155/2009/657369 [doi]
LID - 657369
AB  - Dendritic cells (DCs) are potent antigen-presenting cells and play a central role 
      in the initiation and regulation of primary immune responses. Therefore, their 
      use for the active immunotherapy against cancers has been studied with 
      considerable interest. The fusion of DCs with whole tumor cells represents in 
      many ways an ideal approach to deliver, process, and subsequently present a broad 
      array of tumor-associated antigens, including those yet to be unidentified, in 
      the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine 
      stimulates potent antitumor immunity in the animal tumor models. In the human 
      studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of 
      tumor cells that are used as the fusion partner. In the clinical trials, clinical 
      and immunological responses were observed in patients with advanced stage of 
      malignant tumors after being vaccinated with DC/tumor fusion cells, although the 
      antitumor effect is not as vigorous as in the animal tumor models. This review 
      summarizes recent advances in concepts and techniques that are providing new 
      impulses to DCs/tumor fusions-based cancer vaccination.
FAU - Koido, Shigeo
AU  - Koido S
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Tokyo 277-8567, Japan. shigeo 
      koido@jikei.ac.jp
FAU - Hara, Eiichi
AU  - Hara E
FAU - Homma, Sadamu
AU  - Homma S
FAU - Namiki, Yoshihisa
AU  - Namiki Y
FAU - Ohkusa, Toshifumi
AU  - Ohkusa T
FAU - Gong, Jianlin
AU  - Gong J
FAU - Tajiri, Hisao
AU  - Tajiri H
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100218
PL  - Egypt
TA  - Clin Dev Immunol
JT  - Clinical & developmental immunology
JID - 101183692
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Antigen Presentation
MH  - *Cancer Vaccines
MH  - Cell Differentiation
MH  - Cell Fusion/*methods/trends
MH  - Clinical Trials as Topic
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/immunology/*metabolism/pathology
MH  - Humans
MH  - Neoplasms/*immunology/pathology/*therapy
PMC - PMC2825547
EDAT- 2010/02/26 06:00
MHDA- 2010/06/15 06:00
PMCR- 2010/02/18
CRDT- 2010/02/26 06:00
PHST- 2009/10/17 00:00 [received]
PHST- 2009/12/09 00:00 [accepted]
PHST- 2010/02/26 06:00 [entrez]
PHST- 2010/02/26 06:00 [pubmed]
PHST- 2010/06/15 06:00 [medline]
PHST- 2010/02/18 00:00 [pmc-release]
AID - 10.1155/2009/657369 [doi]
PST - ppublish
SO  - Clin Dev Immunol. 2009;2009:657369. doi: 10.1155/2009/657369. Epub 2010 Feb 18.